Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

MALDI ToF Spectrometer

By Drug Discovery Trends Editor | May 26, 2010

spiralJEOL USA announced the introduction of the company’s first commercially available MALDI-TOF mass spectrometer, the JEOL JMS-S3000 SpiralTOF. The SpiralTOF reinvents Time-of-Flight ion optics with an extended flight length in a compact footprint, delivering a resolving power of greater than 60,000 (FWHM) over a wide mass range of m/z 10-30,000 – the highest resolving power of all commercial MALDI-TOF systems.

JEOL’s patented technology consists of a staggered figure-8 ion trajectory of 17 meters.  By refocusing the ion packets during each turn, the divergence of the ions is reduced over the flight distance.   The SpiralTOF ion optical system is engineered to overcome the limits of delayed extraction with kinetic energy convergence resulting in high sensitivity, resolving power and mass accuracy (less than 1ppm) over a wide mass range.  

To meet the diverse needs of researchers, the SpiralTOF is available in four configurations:

• MALDI-TOF MS with unsurpassed high mass resolving power and high mass accuracy.
• Linear TOF option for high sensitivity analysis of high molecular weight samples and/or those that undergo post-source decay
• TOF/TOF option for acquiring high energy collision-induced dissociation (CID) product ion spectra of monoisotopically selected precursor ions
• TOF/TOF plus Linear TOF for full analytical capability 

With the addition of the SpiralTOF to its mass spectrometer product line, JEOL makes available a unique analytical instrument for proteomics, synthetic polymers, materials, and biomolecules.  

JEOL offers a full suite of mass spectrometry systems: the first commercially-available open air ion source, Direct Analysis in Real Time (DART), paired with its AccuTOFTM-DART Time-of-Flight mass spectrometer; the GC-TOF AccuTOF-GCv mass spectrometer; the JEOL MStation double focusing magnetic sector mass spectrometer; and the GCMate II benchtop GC/MS.  Additionally, a family of 300 to 930MHz NMR spectrometers completes its chemical analysis product line.

JEOL USA


Filed Under: Drug Discovery

 

Related Articles Read More >

In door grow hemp. Cannabis at the beginning of flowering. Legal Marijuana cultivation in the home. Green background of leaves. Young cannabis plant. Medicinal indica with CBD.
Why Schedule III cannabis could be a win for Big Pharma
Red blood cells macro over red eritrosit background. Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Platelet-inspired nanoparticle delivers drugs directly where they are needed
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
China’s biopharma sector enters ‘innovation 2.0’ era
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE